AHG Akso Health Group - Fundamental Analysis

BEARISH

AHG Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Medical Distribution

Current Price Live

$1.49

52W High

$2.1

52W Low

$0.83

Overview AI Snowflake Price Valuation Profitability Growth Health Peers

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Feb 07, 2026

Market cap

$818.31M

P/E

N/A

ROE

-80.3%

Profit margin

N/A

Debt/Equity

0.01

Dividend yield

N/A

AI Analysis

Confidence Score

85%

Analysis Accuracy

AHG's Piotroski F-Score of 5/9 indicates a borderline stable financial health, but its negative profitability metrics—particularly a -80.26% ROE and -43.12% operating margin—signal severe operational distress. The absence of an Altman Z-Score and the company's negative earnings, combined with a 415.8% YoY revenue surge driven by one-time or non-recurring factors, raise serious sustainability concerns. Despite a strong 3-year return of +246.5%, the stock trades at an extreme Price/Sales of 55.37 and a Price/Book of 4.13, suggesting a significant premium to intrinsic value. The lack of dividend, weak insider sentiment, and negative technical trend further undermine investor confidence.

Key Strengths

Exceptional 415.8% YoY revenue growth, indicating strong top-line momentum

Extremely high current and quick ratios (14.20 and 12.83) suggest strong short-term liquidity

Minimal debt (Debt/Equity of 0.01) reduces financial leverage risk

Positive insider sentiment (40/100) indicates some internal confidence

Strong 3-year price performance (+246.5%) reflects market optimism despite fundamentals

Key Risks

Negative operating margin (-43.12%) and gross margin (-1.91%) indicate deep operational inefficiencies

Negative ROE (-80.26%) and ROA (-1.37%) signal poor capital utilization and declining profitability

No Piotroski F-Score above 6 and no Altman Z-Score imply high financial distress risk

Extreme valuation multiples (Price/Sales: 55.37, Price/Book: 4.13) suggest overvaluation relative to earnings

Negative earnings growth (-144.1% YoY) and inconsistent earnings surprises undermine credibility

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

Weak

Key drivers: Negative profitability and high valuation multiples, Lack of sustainable earnings growth, Low Piotroski F-Score and missing Altman Z-Score

Confidence

88%

Value

25/100

Valuation metrics suggest a significant premium to fundamental value; no reliable fair value benchmark exists.

Positives

Low debt levels (Debt/Equity: 0.01)
High liquidity (Current Ratio: 14.20)

Watchpoints

Price/Sales of 55.37 is extremely high
Price/Book of 4.13 is elevated
No Graham Number or intrinsic value available

Future

45/100

Growth is revenue-driven but not yet profitable; sustainability is questionable.

Positives

415.8% YoY revenue growth indicates strong top-line expansion
Recent 1M and 3Y returns show strong momentum

Watchpoints

Earnings growth is negative (-144.1% YoY)
No forward P/E or PEG ratio available
Q/Q EPS growth is -400.0%, indicating deterioration

Past

30/100

Past performance is driven by price volatility, not earnings consistency.

Positives

Historical 3-year return of +246.5% shows strong price appreciation
Some quarters beat estimates (e.g., 2018-02-13: +74.2% surprise)

Watchpoints

Consistent negative earnings and losses
Large negative surprises (e.g., 2018-12-03: -173.5%)
Inconsistent earnings progression

Health

35/100

Financial health is compromised by poor profitability despite strong liquidity and low leverage.

Positives

Extremely low debt (Debt/Equity: 0.01)
High current and quick ratios (14.20, 12.83)

Watchpoints

Piotroski F-Score of 5/9 (borderline stable, not strong)
No Altman Z-Score available (critical red flag)
Negative ROE, ROA, and operating margin

Dividend

0/100

No dividend policy; not applicable for income investors.

Positives

No standout positives identified.

Watchpoints

No dividend yield or payout ratio
Dividend strength: 0/100

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$1.49

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for AHG and closest competitors.

Updated 2026-02-06

Company	5Y	3Y	1Y	6M	1M	1W
AHG Akso Health Group Primary	-40.6%	+246.5%	+7.2%	-12.9%	+8.0%	+4.9%
ABUS Arbutus Biopharma Corporation Peer	-0.5%	+54.7%	+24.1%	+18.9%	+3.1%	+7.3%
AMN AMN Healthcare Services, Inc. Peer	-72.8%	-78.8%	-26.3%	+3.5%	+28.0%	+7.7%
BGM BGM Group Ltd. Peer	-90.8%	-38.2%	-66.0%	-64.4%	-12.5%	0.0%
ABCL AbCellera Biologics Inc. Peer	-92.5%	-65.8%	-3.2%	-30.8%	-29.0%	-1.9%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

4.13

55.37

155.15

-1292.99

$818.31M

Profitability

Profit margins and return metrics

Profit Margin N/A

Operating Margin -43.12%

Gross Margin -1.91%

ROE -80.26%

ROA -1.37%

Growth

Revenue and earnings growth rates

Revenue Growth +415.8%

Earnings Growth N/A

Q/Q Revenue Growth N/A

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.01

Low debt

Current Ratio

14.2

Strong

Quick Ratio

12.83

Excellent

Cash/Share

$0.11

Quarterly Earnings History

EPS performance vs analyst estimates

2019-09-18

$-0.45

2019-06-18

$0.15

+150.0% surprise

2019-02-28

$-0.6

+23.1% surprise

2018-12-03

$-1.08

-173.5% surprise

Healthcare Sector Comparison

Comparing AHG against 146 companies in the Healthcare sector (11 bullish, 60 neutral, 75 bearish)

Return on Equity (ROE)

-80.26%

This Stock

-56.86%

Sector Avg

+41.1% (Excellent)

Debt to Equity

0.01

This Stock

2.68

Sector Avg

-99.6% (Less Debt)

Revenue Growth

415.8%

This Stock

62.23%

Sector Avg

+568.1% (Fast Growth)

Current Ratio

14.2

This Stock

3.45

Sector Avg

+311.6% (Stronger)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
AHG Akso Health Group	BEARISH	$818.31M	-	-80.3%	-%	$1.49
ABUS Arbutus Biopharma Corporation	BEARISH	$821.22M	-	-45.9%	-289.4%	$4.27
AMN AMN Healthcare Services, Inc.	BEARISH	$787.1M	-	-35.9%	-10.1%	$20.49
BGM BGM Group Ltd.	BEARISH	$746.32M	-	-16.5%	-26.3%	$3.72
ABCL AbCellera Biologics Inc.	BEARISH	$909.98M	-	-16.8%	-%	$3.04

Past News Coverage

Recent headlines mentioning AHG from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V1 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends